Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997031016 - NEW INHIBITORS OF SH2-MEDIATED PROCESSES

Publication Number WO/1997/031016
Publication Date 28.08.1997
International Application No. PCT/US1997/002636
International Filing Date 21.02.1997
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 5/107 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
10Tetrapeptides
107the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 5/1016
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
10Tetrapeptides
1002with the first amino acid being neutral
1016and aromatic or cycloaliphatic
Applicants
  • ARIAD PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • LYNCH, Berkley, A.
  • WEIGELE, Manfred
Agents
  • BERSTEIN, David, L.
Priority Data
60/012,20323.02.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEW INHIBITORS OF SH2-MEDIATED PROCESSES
(FR) NOUVEAUX INHIBITEURS DES PROCESSUS LIES A LA PRESENCE DE SH2
Abstract
(EN)
This invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, where A is H, R1, -CO-R1 or -CO-OR1 where R1 is a substituted or unsubstituted alkyl, heteroalkyl, aryl or heteroaryl group and J is H or NO2. L-forms of the compounds are currently preferred, although D- forms and racemic mixtures are also encompassed by this invention.
(FR)
L'invention se rapporte à des composés représentés par la formule (I) et à des sels pharmaceutiquement acceptables de ces composés. Dans la formule (I), A est H, R1, -CO-R1 ou -CO-OR1, R1 étant un groupe alkyle, hétéroalkyle, aryle ou hétéroaryle substitué ou non substitué et J étant H ou NO2. Bien que les formes L de ces composés soient actuellement préférées, l'invention englobe également des formes D et des mélanges racémiques.
Also published as
Latest bibliographic data on file with the International Bureau